SCHEMBL287047

SCHEMBL287047

CC(C)(C)OC(=O)Nc1cccc2c1CC(=O)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
NR1I3 Q14994 3/20 0.39
PRMT5 O14744 2/20 0.39
WDR77 Q9BQA1 2/20 0.39
TRPV1 Q8NER1 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DRD2 P14416 1/20 0.38
LIPE Q05469 1/20 0.38
METAP1 P53582 1/20 0.37
POLB P06746 1/20 0.37
DHPS P49366 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23385619 0.88 ALDH1A1 (0.47) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL30060774 0.88 ALDH1A1 (0.47) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL3880943 0.85 ALDH1A1 (0.45) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL23334164 0.82 ALDH1A1 (0.58) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL25144741 0.82 ALDH1A1 (0.55) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL8669256 0.80 NPC1 (0.57) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL5129173 0.79 ALDH1A1 (0.44) ALDH1A1LMNAMEN1THRATHRB
SCHEMBL23059537 0.78 TRPV1 (0.51) TRPV1
SCHEMBL23059536 0.78 TRPV1 (0.51) TRPV1
SCHEMBL12930805 0.78 TRPV1 (0.51) TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4019485-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVES Mochida Pharmaceutical Co., Ltd. (JP) 2022-06-29 EP disclosed
US-20220009898-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2022-01-13 US disclosed
WO-2021038889-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE 持田製薬株式会社 2021-03-04 WO disclosed
EP-2427436-B1 SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS GRUENENTHAL GMBH (DE) 2013-01-09 EP disclosed
EP-2427436-B1 SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS GRUENENTHAL GMBH (DE) 2013-01-09 EP disclosed
US-8334315-B2 Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2012-12-18 US disclosed
US-8334315-B2 Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2012-12-18 US disclosed
US-8334315-B2 Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2012-12-18 US disclosed
EP-2427436-A1 SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2012-03-14 EP disclosed
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2011-01-06 US disclosed
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2011-01-06 US disclosed
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2011-01-06 US disclosed
WO-2010127855-A1 SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2010-11-11 WO disclosed
WO-2010127855-A1 SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003795-A1 Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands TRPV1, UTS2R, CNR2 ALDH1A1 2165/4885LMNA 3573/4885MEN1 4682/4885
US-20220009898-A1 METHOD FOR PRODUCING HETEROCYCLIDENE ACETAMIDE DERIVATIVE COASY, NAAA, AADAC ALDH1A1 139/4885LMNA 3782/4885MEN1 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.